Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Helicidine
- Development stage
- Phase 4
- Lead developer
- Therabel Group
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Oral
01
Overview
Helicidine is a peripheral-acting antitussive medication derived from the mucoglycoprotein of the Burgundy snail (*Helix pomatia L.*). Developed and marketed by Therabel Group, it is primarily used to treat dry and irritating coughs associated with respiratory tract disorders. The drug functions by exerting a bronchorelaxant effect, which is believed to be mediated through the release of prostaglandins. It has been available in France for over 40 years and is typically formulated as a 10% syrup. It is indicated for adults and children over the age of two, but is contraindicated in infants due to the risk of bronchial congestion.
- Brand names
- HELICIDINE
- Other names
- HélicidineHelix pomatia extractSnail mucus extract
Beyond the preview
Go deeper on Helicidine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Helicidine.